Original research article| Volume 95, ISSUE 6, P538-543, June 2017

Vaginal misoprostol prior to intrauterine device insertion in women delivered only by elective cesarean section: a randomized double-blind clinical trial



      The current study aims to evaluate if vaginal misoprostol (400 mcg) administered prior to intrauterine device (IUD) insertion increases the ease and success of insertion among women who had delivered only by elective cesarean delivery (CD).

      Study design

      The current study was a randomized, double-blind, placebo-controlled trial conducted in Assiut Women's Health Hospital, Egypt, between the 1st of April 2015 and the 31st of March 2016 and included women who delivered only by elective CD. One hundred forty women were randomized into two groups; misoprostol group received two misoprostol 400-mcg tablets vaginally, and placebo group received two placebo tablets 3 h before a copper T380A IUD insertion. The primary outcome measure was the difference in the ease of insertion score using a 10-cm visual analog scale between both groups with 0 = very easy insertion, and 10 = terribly difficult insertion.


      The ease of insertion score was lower in the misoprostol group (2.2±0.5 vs. 4.2±0.5, p=.0001) with higher number of successful IUD insertions than the placebo group (69 [98.6%] vs. 61 [87.1%], p=.009). The mean pain score reported by the women was lower in misoprostol group (2.7±0.6 vs. 4.3±0.8) with higher level of satisfaction from the whole procedure (8.9±0.4 vs. 7.9±0.2) with p=.001 for both.


      Misoprostol 400 mcg vaginally prior to IUD insertion eases and increase the success of insertion with reduction of pain among women who had delivered only by elective CD.


      The use of vaginal misoprostol before IUD insertion in women who had never delivered vaginally before may increase the ease and success of insertion. Moreover, it may reduce the pain felt by women during the procedure.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Obstet Gynecol. 2012; 120: 983-988
        • Winner B.
        • Peipert J.F.
        • Zhao Q.
        • Buckel C.
        • Madden T.
        • Allsworth J.E.
        • et al.
        Effectiveness of long-acting reversible contraception.
        N Engl J Med. 2012; 366: 1998-2007
        • d'Arcangues C.
        Worldwide use of intrauterine devices for contraception.
        Contraception. 2007; 75: S2-S7
        • Asker C.
        • Stokes-Lampard H.
        • Beavan J.
        • Wilson S.
        What is it about intrauterine devices that women find unacceptable? Factors that make women non-users: a qualitative study.
        J Fam Plann Reprod Health Care. 2006; 32: 89-94
        • Hubacher D.
        • Reyes V.
        • Lillo S.
        • Zepeda A.
        • Chen P.L.
        • Croxatto H.
        Pain from copper intrauterine device insertion: randomized trial of prophylactic ibuprofen.
        Am J Obstet Gynecol. 2006; 195: 1272-1277
        • Lopez L.M.
        • Bernholc A.
        • Zeng Y.
        • Allen R.H.
        • Bartz D.
        • O'Brien P.A.
        • et al.
        Interventions for pain with intrauterine device insertion.
        Cochrane Database Syst Rev. 2015; 29: CD007373
        • Kass-Wolff J.H.
        • Fisher J.E.
        Evidence-based pain management for endometrial biopsies and IUD insertions.
        Nurse Pract. 2014; 39: 43-50
        • Barber E.L.
        • Lundsberg L.S.
        • Belanger K.
        • Pettker C.M.
        • Funai E.F.
        • Illuzzi J.L.
        Indications contributing to the increasing cesarean delivery rate.
        Obstet Gynecol. 2011; 118: 29-38
        • Batukan C.
        • Ozgun M.
        • Ozcelik B.
        • Aygen E.
        • Sahin Y.
        • Turkyilmaz C.
        Cervical ripening before operative hysteroscopy in premenopausal women: a randomized, double-blind, placebo-controlled comparison of vaginal and oral misoprostol.
        Fertil Steril. 2008; 89: 966-973
        • Allen R.H.
        • Goldberg A.B.
        Cervical dilation before first-trimester surgical abortion (<14 weeks’ gestation). SFP guideline 20071.
        Contraception. 2007; 76: 139-156
        • Saav I.
        • Aronsson A.
        • Marions L.
        • Stephansson O.
        • Gemzell-Danielsson K.
        Cervical priming with sublingual misoprostol prior to insertion of an intrauterine device in nulliparous women: a randomized controlled trial.
        Hum Reprod. 2007; 22: 2647-2652
        • Scavuzzi A.
        • Souza A.S.
        • Costa A.A.
        • Amorim M.M.
        Misoprostol prior to inserting an intrauterine device in nulligravidas: a randomized clinical trial.
        Hum Reprod. 2013; 28: 2118-2125
        • Dijkhuizen K.
        • Dekkers O.M.
        • Holleboom C.A.
        • de Groot C.J.
        • Hellebrekers B.W.
        • van Roosmalen G.J.
        • et al.
        Vaginal misoprostol prior to insertion of an intrauterine device: an RCT.
        Hum Reprod. 2011; 26: 323-329
        • Edelman A.
        • Schaefer E.
        • Olson A.
        • Van Houten L.
        • Bedarnek P.
        • Leclair C.
        • et al.
        Effects of prophylactic misoprostol administration prior to intrauterine device insertion in nulliparous women.
        Contraception. 2011; 84: 234-239
        • Ibrahim Z.M.
        • Sayed Ahmed W.A.
        Sublingual misoprostol prior to insertion of a T380A intrauterine device in women with no previous vaginal delivery.
        Eur J Contracept Reprod Health Care. 2013; 18: 300-308
        • World Health Organization
        Medical eligibility criteria for contraceptive use.
        WHO, Geneva (Switzerland)2010
        • Bouhassira D.
        • Attal N.
        • Alchaar H.
        • Boureau F.
        • Brochet B.
        • Bruxelle J.
        • et al.
        Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4).
        Pain. 2005; 114: 29-36
        • Tang O.S.
        • Gemzell-Danielsson K.
        • Ho P.C.
        Misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects.
        Int J Gynaecol Obstet. 2007; 99: S160-S167
        • Fiala C.
        • Gemzell-Danielsson K.
        • Tang O.S.
        • von Hertzen H.
        Cervical priming with misoprostol prior to transcervical procedures.
        Int J Gynecol Obstet. 2007; 99: S168-S171
        • Apte G.
        • Nelson P.
        • Brismée J.M.
        • Dedrick G.
        • Justiz III, R.
        • Sizer Jr., P.S.
        Chronic female pelvic pain—part 1: clinical pathoanatomy and examination of the pelvic region.
        Pain Pract. 2012; 12: 88-110
        • Ofili-Yebovi D.
        • Ben-Nagi J.
        • Sawyer E.
        • Yazbek J.
        • Lee C.
        • Gonzalez J.
        • et al.
        Deficient lower-segment cesarean section scars: prevalence and risk factors.
        Ultrasound Obstet Gynecol. 2008; 31: 72-77
        • Bahamondes M.V.
        • Hidalgo M.M.
        • Bahamondes L.
        • Monteiro I.
        Ease of insertion and clinical performance of the levonorgestrel-releasing intrauterine system in nulligravidas.
        Contraception. 2011; 84: e11-e16
        • Dermish A.
        • Turok D.K.
        • Jacobson J.
        • Murphy P.A.
        • Saltzman H.M.
        • Sanders J.N.
        Evaluation of an intervention designed to improve the management of difficult IUD insertions by advanced practice.
        Contraception. 2016; 93: 533-538
        • Hamoda H.
        • Ashok P.W.
        • Flett G.M.
        • Templeton A.
        A randomized controlled comparison of sublingual and vaginal administration of misoprostol for cervical priming before first-trimester surgical abortion.
        Am J Obstet Gynecol. 2004; 190: 55-59